AMENDMENT – NUMBER ONE AGREEMENTEmployment Agreement • November 9th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
This Amendment Number One (this “Amendment 1”) is effective as of July 2, 2009 by and between Antigenics Inc., a Delaware corporation, having its principle place of business at 3 Forbes Road, Lexington, Massachusetts 02421, USA (the “Company”) and Karen Valentine (the “Executive”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement (defined below).
Contract No. 2Sales Contract • November 9th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances)
The Company, Antigenics, Inc., a Delaware, U.S.A. corporation, hereinafter referred to as the “Seller” in the person of Garo Armen, Chief Executive Officer, on the one part, and ISSI-Strategy LLC, a Russian corporation, hereinafter referred to as the Buyer, in the person of Alexey Shvetz, General Director,, on the other part, concluded the present Contract on the following:
AMENDMENT – NUMBER ONE AGREEMENTEmployment Agreement • November 9th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Massachusetts
This Amendment Number One (this “Amendment 1”) is effective as of July 2, 2009 by and between Antigenics Inc., a Delaware corporation, having its principle place of business at 3 Forbes Road, Lexington, Massachusetts 02421, USA (the “Company”) and Garo Armen (the “Executive”). Capitalized terms not otherwise defined herein shall have the meaning set forth in the Agreement (defined below).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 9th, 2009 • Antigenics Inc /De/ • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated License Agreement (this “Agreement”), effective as of the date of the last signature hereto (the “Restated Effective Date”), is made by and between Antigenics, Inc., a Massachusetts corporation having offices at 3 Forbes Road, Lexington, MA 02421 (“Antigenics”), Elan Pharma International Limited, a private company limited by shares organized under the laws of Ireland with offices at Monksland, Athlone, County Westmeath, Ireland (“EPIL”) and Elan Pharmaceuticals, Inc., a Delaware corporation having an address at 800 Gateway Boulevard, South San Francisco, CA 94080, U.S.A. (“EPI” and together with EPIL, “Elan”). Antigenics and Elan are each referred to herein as a “Party” and collectively, as the “Parties”.
